TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases | Zendy

Rachel A. Freedman | Zendy; Rebecca Gelman | Zendy; Carey K. Anders | Zendy; Michelle Melisko | Zendy; Heather A. Parsons | Zendy; Anne M. Cropp | Zendy; Kelly M. Silvestri | Zendy; Christine M Cotter | Zendy; K. Componeschi | Zendy; Juan M. Marte | Zendy; Roisín M. Connolly | Zendy; Beverly Moy | Zendy; Catherine Van Poznak | Zendy; Kimberly Blackwell | Zendy; Shan Puhalla | Zendy; Rachel C. Jankowitz | Zendy; Karen L. Smith | Zendy; Nuhad K. Ibrahim | Zendy; Timothy J. Moynihan | Zendy; Ciara C. O’Sullivan | Zendy; Julie R. Nangia | Zendy; Polly Niravath | Zendy; Nadine Tung | Zendy; Paula Raffin Pohlmann | Zendy; Robyn Burns | Zendy; Mothaffar F. Rimawi | Zendy; Ian E. Krop | Zendy; Antonio C. Wolff | Zendy; Eric P. Winer | Zendy; Nancy U. Lin | Zendy

Open Access

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

Author(s) -

Rachel A. Freedman,

Rebecca Gelman,

Carey K. Anders,

Michelle Melisko,

Heather A. Parsons,

Anne M. Cropp,

Kelly M. Silvestri,

Christine M Cotter,

K. Componeschi,

Juan M. Marte,

Roisín M. Connolly,

Beverly Moy,

Catherine Van Poznak,

Kimberly Blackwell,

Shan Puhalla,

Rachel C. Jankowitz,

Karen L. Smith,

Nuhad K. Ibrahim,

Timothy J. Moynihan,

Ciara C. O’Sullivan,

Julie R. Nangia,

Polly Niravath,

Nadine Tung,

Paula Raffin Pohlmann,

Robyn Burns,

Mothaffar F. Rimawi,

Ian E. Krop,

Antonio C. Wolff,

Eric P. Winer,

Nancy U. Lin

Publication year - 2019

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.01511

Subject(s) - medicine , lapatinib , capecitabine , neratinib , cohort , metastatic breast cancer , oncology , breast cancer , cancer , trastuzumab , colorectal cancer

Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy for HER2-positive breast cancer brain metastases. Here we report the results from additional study cohorts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

About

Learn

Discover

Explore